
Liquidia Corporation LQDA
€ 30.84
-2.31%
Geschäftsbericht 2025
hinzugefügt 05.03.2026
Liquidia Corporation Langfristige Verbindlichkeiten 2011-2026 | LQDA
Langfristige Verbindlichkeiten Jährlich Liquidia Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 10.3 M | 17 M | 22.5 M | 18 M | 14.6 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 22.5 M | 10.3 M | 16.5 M |
Langfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
40.2 M | - | 2.43 % | $ 254 M | ||
|
Altimmune
ALT
|
4.4 M | $ 3.41 | 2.1 % | $ 300 M | ||
|
Amgen
AMGN
|
37.2 B | $ 350.17 | 0.68 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
69.4 M | $ 19.57 | 0.36 % | $ 915 M | ||
|
I-Mab
IMAB
|
131 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
4.83 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
184 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
2.02 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
101 M | $ 217.82 | -1.83 % | $ 5 B | ||
|
Autolus Therapeutics plc
AUTL
|
50.6 M | $ 1.4 | 1.82 % | $ 357 M | ||
|
Midatech Pharma plc
MTP
|
110 K | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
6.39 M | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
42.1 M | $ 2.64 | 1.15 % | $ 16.6 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
4.15 M | - | - | $ 26.5 M | ||
|
ARCA biopharma
ABIO
|
409 K | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
19.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
1.53 M | - | -10.17 % | $ 12.2 K | ||
|
Benitec Biopharma
BNTC
|
213 K | $ 11.0 | 0.18 % | $ 453 M | ||
|
Acorda Therapeutics
ACOR
|
257 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
79.1 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
4.59 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
12.2 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
541 M | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
2.03 M | - | -52.27 % | $ 4.45 M | ||
|
Adverum Biotechnologies
ADVM
|
27.3 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
244 K | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
16 M | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
189 M | $ 1.58 | 3.62 % | $ 185 M | ||
|
Cellectis S.A.
CLLS
|
109 M | $ 3.35 | 0.3 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
553 K | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
277 M | $ 12.83 | 0.71 % | $ 773 M | ||
|
Atreca
BCEL
|
12.6 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
78.7 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
2 B | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
4.82 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
3.35 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
81.7 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
1.93 M | - | -74.18 % | $ 955 K | ||
|
CorMedix
CRMD
|
924 K | $ 6.29 | 0.64 % | $ 453 K | ||
|
CytomX Therapeutics
CTMX
|
228 M | $ 4.41 | -1.01 % | $ 608 M | ||
|
Checkpoint Therapeutics
CKPT
|
2.47 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
579 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
4.74 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
112 M | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
31.3 M | $ 2.12 | 1.2 % | $ 198 M | ||
|
Denali Therapeutics
DNLI
|
113 M | $ 20.92 | 3.69 % | $ 3.44 B | ||
|
Dyadic International
DYAI
|
8.14 M | $ 0.89 | -5.85 % | $ 25.6 M | ||
|
Akero Therapeutics
AKRO
|
1.52 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
25.6 M | $ 4.26 | 0.47 % | $ 707 M | ||
|
Akouos
AKUS
|
12 M | - | 0.23 % | $ 488 M |